13.05.19
NPUK INTERACTIVE WORKSHOP - REGISTER NOW! For all health professionals, clinicians and pharma reps who want to join us for the Interactive Workshop this form is for you, please register by the 6th September.
Read more13.05.19
NPUK ANNUAL FAMILY CONFERENCE - REGISTER NOW! Don't miss out on your chance to join the NPUK Annual Family Conference, the biggest and best event in our calendar! Which this year will be held on the 20th-22nd September at Wyboston Lakes, Bedfordshire.
Read more09.05.19
An update from Mallinckrodt Pharmaceuticals regarding their study VTS-270-303...
Read more07.05.19
We are happy to announce that the latest edition of NPUK News (Spring 2019) is here, full to the brim with everything our community needs - there's fundraising stories, events news, updates from staff and community members...and so much more!
Read more15.03.19
ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.
Read more
